This article was originally published in The Gray Sheet
Executive SummarySeven-year, multi-billion dollar corporate partnership effective in July extends existing agreements between Premier and Abbott and adds new relationships in patient-controlled analgesia, anesthesia trays, hematology, injectable drugs and pharmaceuticals
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.